Introduction {#Sec1}
============

Coronavirus disease 2019 (COVID-19) pandemic has rapidly spread around the world from Jan-2020, with more than 14,000,000 cases confirmed so far \[[@CR1]\]. Although primary affecting the respiratory system, central and peripheral neurological manifestations associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have been increasingly reported \[[@CR2]--[@CR4]\]. In detail, several pieces of evidence suggested an association between SARS-CoV-2 infection and the development of Guillain--Barré Syndrome (GBS) \[[@CR5]--[@CR56]\].

GBS represents the most common cause of acute flaccid paralysis \[[@CR57]\]. The classic form is an immune-mediated acute-onset demyelinating polyradiculoneuropathy (acute inflammatory demyelinating polyneuropathy---AIDP) typically presenting with ascending weakness, loss of deep tendon reflexes, and sensory deficits. Diagnosis of GBS relies on the results of clinical, electrophysiological, and cerebrospinal fluid (CSF) examinations (classically albuminocytological dissociation) \[[@CR57]--[@CR59]\]. The clinical spectrum of GBS encompasses a classic sensorimotor form, Miller Fisher syndrome (MFS), bilateral facial palsy with paraesthesia, pure motor, pure sensory, paraparetic, pharyngeal--cervical--brachial variants, polyneuritis cranialis (GBS--MFS overlap), and Bickerstaff brainstem encephalitis \[[@CR57]--[@CR60]\]. As regard electrophysiological features, three main subtypes are recognized: AIDP, acute motor axonal neuropathy (AMAN), and acute motor sensory axonal neuropathy (AMSAN) \[[@CR57], [@CR58], [@CR61]\]. Peripheral nerve damage is thought to be provoked by an aberrant immune response to infections, in some cases driven by the production of autoreactive antibodies (anti-ganglioside antibodies) \[[@CR57]--[@CR59]\]. Potential triggering pathogens include both viruses \[e.g., cytomegalovirus (CMV), Epstein--Barr virus (EBV), influenza virus, hepatitis E virus, and Zika virus\] and bacteria (e.g., *Campylobacter Jejuni, Mycoplasma Pneumoniae*) \[[@CR57], [@CR58], [@CR62]\]. However, a relationship with other events has been also described (e.g., vaccinations, surgery, administration of checkpoint inhibitors, and malignancy) \[[@CR57], [@CR58]\]. Given that a potential causal association with beta-coronaviruses \[Middle East Respiratory Syndrome (MERS-CoV)\] has already been speculated, the relationship between COVID-19 and GBS deserves undoubtedly further attention \[[@CR63], [@CR64]\].

With this background, our systematic review aimed to provide a comprehensive and updated overview of all case reports and series of COVID-19-related GBS to identify predominant clinical, laboratory, and neurophysiological patterns and to discuss the possible underlying pathophysiology.

Methods {#Sec2}
=======

We performed a systematic review according to the SALSA (Search, Appraisal, Synthesis, and Analysis) analytic framework \[[@CR65]\]. We screened in PubMed and Google Scholar databases for all case descriptions of GBS associated with COVID-19 that were published from January 1st 2020 up to July 20th 2020. Keywords (including all commonly used abbreviations of these terms) used in the search strategy were as follows: \["acute autoimmune neuropathy" OR "acute inflammatory demyelinating polyneuropathy" OR "acute inflammatory demyelinating polyradiculoneuropathy," OR "acute inflammatory polyneuropathy" OR "Demyelinating Polyradiculoneuropathy" OR "Guillain--Barre Syndrome" OR "Guillain--Barre" OR ""Miller--Fisher" OR "Bickerstaff encephalitis" OR "AIDP" OR "AMAN" OR "AMSAN" OR polyneuritis cranialis\] AND \["COVID-19" OR "Wuhan coronavirus" OR "novel coronavirus" OR "novel coronavirus 2019" OR "SARS" OR "SARS-CoV-2"\]. Suitable references were also identified in the authors' archives of scientific literature on GBS. We restricted our search to studies published in English, Spanish, or Italian. Publications that were not peer-reviewed were excluded from this study. PRISMA criteria were applied. For each case, we extracted data concerning demographic and clinical variables, results of diagnostic investigations, and outcome. If the GBS clinical variant \[[@CR57]\] or the electrophysiological subtype \[[@CR61]\] was not explicitly reported in the paper, we reconstructed it, when possible, from reported details. We also classified the diagnostic certainty of all cases according to the Brighton Criteria \[[@CR66]\]. Searches were performed by SAR, AA, and MF. The selection of relevant articles was shared with all authors.

For statistical analysis, we used IBM SPSS Statistics version 21 (IBM, Armonk, NY, USA). Based on the distribution of values, continuous data were expressed as mean ±  standard deviation or as  median and interquartile range (IQR). Depending on the number of groups and data distribution, we applied the t test, the Mann--Whitney *U* test or the Kruskal--Wallis test (followed by Dunn--Bonferroni post hoc test). All reported *p* values were adjusted for multiple comparisons. We adopted the Chi-square test for categorical variables. Differences were considered statistically significant at*p* \< 0.05.

For the present study, no authorization to an Ethics Committee was asked, because the original reports, nor this work, provided any personal information of the patients.

Results {#Sec3}
=======

Our literature search identified 101 papers, including 37 case reports, 12 case series, 3 reviews with case reports, 42 reviews, 4 letters, 1 original article, 1 point of view, and 1 brief report. Four and one patients were excluded from the analysis because of a missing laboratory-proven SARS-CoV-2 infection or an ambiguous GBS diagnosis \[disease course resembling chronic inflammatory demyelinating neuropathy (CIDP)\], respectively. A total of 52 studies were included in the final analysis (total patients = 73) \[[@CR5]--[@CR56]\]. All data concerning the analyzed patients are reported in Table [1](#Tab1){ref-type="table"}. For one case \[[@CR20]\], most clinical and diagnostic details were not reported; therefore, many of our analyses were limited to 72 patients.

Epidemiological distribution and demographic characteristics of the patients {#Sec4}
----------------------------------------------------------------------------

To date, GBS cases (*n* = 73) were reported from all continents except Australia. In details, patients were originally from Italy (*n* = 20), Iran (*n* = 10), Spain (*n* = 9), USA (*n* = 8), United Kingdom (*n* = 5), France (*n* = 4), Switzerland (*n* = 4), Germany (*n* = 3), Austria (*n* = 1), Brazil (*n* = 1), Canada (*n* = 1), China (*n* = 1), India (*n* = 1), Morocco (*n* = 1), Saudi Arabia (*n* = 1), Sudan (*n* = 1), The Netherlands (*n* = 1), and Turkey (*n* = 1) (Table [1](#Tab1){ref-type="table"}, Fig. [1](#Fig1){ref-type="fig"}). The mean age at onset was 55 ± 17 years (min 11--max 94), including four pediatric cases \[[@CR21], [@CR27], [@CR35], [@CR41]\]. A significative prevalence of men compared to women was noticed (50 vs. 23 cases: 68.5% vs. 31.5%) with no significant difference in age at onset between men and women (mean: 55 ± 18 vs. 56 ± 16 years, *p* = 0.643). Comorbidities were variably reported with no prevalence of a particular disease.Fig. 1Temporal and spatial distribution of reported cases with COVID-19-associated Guillain--Barré syndrome in literature from 1st January until 20th July 2020. The *x*-axis shows the number of described patients. The *y*-axis illustrates the countries of provenience of the cases. In each line, different colours represent the months of April, May, June, and July (\* until 20th July) 2020, in which the cases were published. Abbreviations: UK, United Kingdom, USA, United States of America

Clinical picture, diagnosis, and therapy of COVID-19 {#Sec5}
----------------------------------------------------

All reported GBS cases (*n* = 72) except two were symptomatic for COVID-19 with various severity. Most common manifestations of COVID-19 included fever (73.6%, 53/72), cough (72.2%, 52/72), dyspnea and/or pneumonia (63.8%, 46/72), hypo-/ageusia (22.2%, 16/72), hypo-/anosmia (20.8%, 15/72), and diarrhea (18.1%, 13/72). One of the two asymptomatic subjects never developed fever, respiratory symptoms, or pneumonia \[[@CR10]\], whereas the other patient showed an asymptomatic pneumonia at chest computed tomography (CT) \[[@CR12]\]. In all but six patients with available data \[[@CR22], [@CR24], [@CR36], [@CR44], [@CR45], [@CR52]\], SARS-CoV-2 RT-PCR with naso- or oropharyngeal swab or fecal exam was positive at first or following tests. Nevertheless, these six patients tested positive at SARS-CoV-2 serology. In four patients, the laboratory exam for the diagnostic confirmation was not specified \[[@CR20], [@CR40]\]. Typical "ground glass" aspects at chest-CT or similar findings at CT, Magnetic Resonance Imaging (MRI) or X-ray compatible with COVID-19 interstitial pneumonia were reported in 40 cases. The detailed therapies for COVID-19 are described in Table [1](#Tab1){ref-type="table"}.

Clinical features of GBS spectrum {#Sec6}
---------------------------------

In all (*n* = 72) but four patients \[[@CR10], [@CR37], [@CR40], [@CR56]\], GBS manifestations developed after those of COVID-19 \[median (IQR): 14 (7--20), min 2--max 33 days\]. Differently, COVID-19 symptoms began concurrent in one case \[[@CR37]\], 1 day \[[@CR40]\] and 8 days \[[@CR55]\] after GBS onset in two other cases and never developed in another one \[[@CR10]\] (Table [1](#Tab1){ref-type="table"}). Common clinical manifestations at onset included sensory symptoms (72.2%, 52/72) alone or in combination with paraparesis or tetraparesis (65.2%, 47/72, respectively). Cranial nerve involvement (e.g., facial, oculomotor nerves) was less frequently described at onset (16.7%, 12/72). Moreover, all cases but one \[[@CR26]\] showed lower limbs or generalized areflexia, whereas in 37.5% (27/72) of the cases, gait ataxia was reported at onset or during the disease course. Even if ascending weakness evolving into flaccid tetraparesis (76.4%, 55/72) and spreading/persistence of sensory symptoms (84.7%, 61/72) represented the most common clinical evolutions, 50.0% (36/72) and 23.6% (17/72) patients showed cranial nerve deficits and dysphagia, respectively, during disease course (Table [1](#Tab1){ref-type="table"}). Moreover, 36.1% (26/72) of the patients developed respiratory symptoms, and some of them evolved to respiratory failure (Table [1](#Tab1){ref-type="table"}). Autonomic disturbances were rarely reported (16.7%, 12/72). In cases with MFS/MFS-GBS overlap, areflexia, oculomotor disturbances, and ataxia were present in 100% (9/9), 66.7% (6/9) and 66.7% (6/9), respectively \[[@CR8], [@CR19], [@CR23], [@CR30], [@CR32], [@CR33], [@CR43], [@CR44]\]. The median of time to nadir was calculated in 40 patients with available data and resulted 4 days (IQR 3--9) (Table [1](#Tab1){ref-type="table"}).

Results of electrophysiological, CSF, biochemical, and neuroimaging investigations {#Sec7}
----------------------------------------------------------------------------------

Detailed electroneurography results were reported in 84.9% (62/73) of the cases. Specifically, 77.4% (48/62) cases showed a pattern compatible with a demyelinating polyradiculoneuropathy. In contrast, axonal damage was prominent in 14.5% (9/62). In a minority of the patients (8.1%), a mixed pattern was reported (5/62). Regarding CSF analysis (full results were available in 59 out of 73 cases), the classical albuminocytological dissociation (cell count \< 5/µl with elevated CSF proteins) was detected in 71.2% of the cases (42/59) with a median CSF protein of 100.0 mg/dl (min: 49, max: 317 mg/dl). Mild pleocytosis (i.e., cell count ≥ 5/µl), with a maximum cell count of 13/µl, was evident in 5/59 cases (8.5%). Furthermore, CSF SARS-CoV-2 RNA was undetectable in all tested patients (*n* = 31) (Table [1](#Tab1){ref-type="table"}).

Detailed blood haematological and biochemical examinations showed variably leucocytosis (*n* = 4), leucopenia (*n* = 17), thrombocytosis (*n* = 3), thrombocytopenia (*n* = 5), and increased levels of C-reactive protein (CRP) (*n* = 22), erythrocyte sedimentation rate (*n* = 4), [d]{.smallcaps}-Dimer (*n* = 5), fibrinogen (*n* = 3), ferritin (*n* = 3), LDH (*n* = 7), IL-6 (*n* = 4), IL-1 (*n* = 3), IL-8 (*n* = 3), and TNF-α (*n* = 3) (Table [1](#Tab1){ref-type="table"}).

Furthermore, anti-GD1b and anti-GM1 antibodies were positive in one patient with MFS \[[@CR23]\] and in one with classic sensorimotor GBS \[[@CR13]\], respectively, whereas 33 cases tested negative (one in equivocal range) for anti-ganglioside antibodies.

Cranial and spinal MRI scans were performed in a minority of the patients (23/73, 31.5%). Five patients (three cases with AIDP \[[@CR9], [@CR12], [@CR25]\], one case with MFS \[[@CR30]\], and one case with bilateral facial palsy with paresthesia \[[@CR52]\]) showed cranial nerve contrast enhancement in the context of correspondent cranial nerve palsies. Moreover, brainstem leptomeningeal enhancement was described in two cases with AIDP, both with clinical cranial nerve involvement \[[@CR18], [@CR46]\]. On the other hand, spinal nerve roots and leptomeningeal enhancement were reported in eight \[[@CR9], [@CR27], [@CR31], [@CR36], [@CR37], [@CR42], [@CR52]\] and two cases \[[@CR17], [@CR46]\], respectively (Table [1](#Tab1){ref-type="table"}).

Distribution of clinical and electrophysiological variants and diagnosis of GBS {#Sec8}
-------------------------------------------------------------------------------

From the clinical point of view, most examined patients presented with a classic sensorimotor variant (70.0%, 51/73), whereas Miller Fisher syndrome, GBS/MFS overlap variants (including polyneuritis cranialis), bilateral facial palsy with paresthesia, pure motor, and paraparetic were described in seven, two, five, four, and one patients, respectively. In three cases, no clinical variant could be established using the reported details (Table [1](#Tab1){ref-type="table"}). In the examined population, 81.8% subjects fulfilled electrophysiological criteria for AIDP (45/55), 12.7% (7/55) for AMSAN, and 5.4% (3/55) for AMAN subtypes. Finally, a specific electrophysiological subtype was not attributable in 18 patients due to the lack of detailed information. The diagnosis of GBS was established based on clinical, CSF, and electrophysiological findings in 44/73 (60.3%) patients, clinical, and electrophysiological data in 18/73 (24.7%) cases, clinical, and CSF data in 8/73 (11.0%), and only clinical findings in 3/73 (4.1%) patients. Indeed, the highest level of diagnostic certainty (level one) was confirmed in 44/73 cases (60.3%). Level two and three were obtained in 24/73 cases (32.9%) and 5/73 (6.8%), respectively (Table [1](#Tab1){ref-type="table"}).

Management of GBS and patient outcomes {#Sec9}
--------------------------------------

All cases with available therapy data (*n* = 70) except ten \[[@CR13], [@CR15], [@CR23], [@CR25], [@CR26], [@CR33], [@CR35]--[@CR37], [@CR41]\] were treated with intravenous immunoglobulin (IVIG) (Table [1](#Tab1){ref-type="table"}). Conversely, plasma exchange and steroid therapy were performed in ten (four of them received also IVIG) and two cases, respectively. In two patients, no therapy was given. Mechanical or non-invasive ventilation was implemented in 21.4% (15/70) and 7.1% (5/70) patients due to worsening of GBS or COVID-19, respectively. At further observation (n = 68), 72.1% (49/68) patients demonstrated clinical improvement with partial or complete remission, 10.3% (7/68) cases showed no improvement, 11.8% (8/68) still required critical care treatment, and 5.8% (4/68) died (Table [1](#Tab1){ref-type="table"}).Table 1Summary of clinical findings, results of diagnostic investigations, and outcome in 73 GBS casesArticleCountryAgeSexGBS clinical pictureCOVID-19 clinical picturePrevious comorbiditiesGBS diagnosisLevel of diagnostic certainty^b^GBS variantDays between COVID-19 symptoms and GBS onsetOnsetDisease courseAutonomic disturbancesRespiratory symptoms/failureTime to Nadir^a^Agosti et al. \[[@CR5]\]Italy68M5 days afterLL weaknessBilateral facial palsy, progressive symmetric ascending flaccid tetraparesis, achilles tendon areflexiaNANoNADry cough associated with fever, dysgeusia, and hyposmiaDyslipidemia, benign prostatic hypertrophy, hypertension, abdominal aortic aneurysmClinical + CSF + electrophysiology1Pure motorAlberti et al. \[[@CR6]\]Italy71M4 days after (no resolution of pneumonia)LL paraesthesiaAscendant weakness, flaccid tetraparesis, hypoesthesia and paraesthesia in the 4 limbs, generalized areflexia, dyspneaNoneYes (concurrent pneumonia)4 days after symptoms onset (24 h after the admission)Fever (low grade), dyspnea, pneumoniaHypertension, treated abdominal aortic aneurysm, treated lung cancerClinical + CSF + electrophysiology1Classic sensorimotorArnaud et al. \[[@CR7]\]France64M23 days afterFast progressive LL weaknessGeneralized areflexia, severe flaccid proximal paraparesis, decreased proprioceptive length-dependent sensitivity and LL pinprick and light touch hypoesthesiaNoneNo4 days after symptoms onsetFever, cough, diarrhea, dyspnea, severe interstitial pneumoniaDM type 2Clinical + CSF + electrophysiology1Classic sensorimotorAssini et al. \[[@CR8]\]Italy55M20 days afterBilateral eyelid ptosis, dysphagia, dysphoniaMasseter weakness, tongue protusion (bilateral hypoglossal nerve paralysis), UL and LL hyporeflexia without muscle weakness, soft palate elevation defectNoneYes (concurrent pneumonia)NAFever, anosmia, ageusia, cough, pneumoniaNAClinical + electrophysiology2Classic sensorimotor overlapping with Miller-FisherAssini et al. \[[@CR8]\]Italy60M20 days afterDistal tetraparesis with right foot drop, autonomic disturbancesUL and LL distal weakness, right foot drop, generalized areflexiaGastroplegia, paralytic ileus, loss of blood pressure controlYes (concurrent pneumonia)NAFever, severe interstitial pneumoniaNAClinical + electrophysiology2Pure motorBigaut et al. \[[@CR9]\]France43M21 days afterUL and LL paraesthesia, distal LL weaknessExtension to midthigh and tips of the finger with ataxia, right peripheral facial nerve palsy, generalized areflexiaNoneNo2 days after symptoms onsetCough, asthenia, myalgia in legs, followed by acute anosmia and ageusia with diarrhea, mild interstitial pneumoniaNAClinical + CSF + electrophysiology1Classic sensorimotorBigaut et al. \[[@CR9]\]France70F10 days afterAcute proximal tetraparesis, distal forelimb and perioral paraesthesiaRespiratory weakness, loss of ambulationNoneYes3 days after symptoms onsetAnosmia, ageusia, diarrhea, asthenia, myalgia, moderate interstitial pneumoniaObesityClinical + CSF + electrophysiology1Classic sensorimotorBracaglia et al. \[[@CR10]\]Italy66FUnknown (due to asymptomatic infection)Acute proximal and distal tetraparesis, lumbar pain and distal tingling sensationLoss of ambulation, difficulty in speeching and swallowing, generalized areflexiaNoneNoNAAsymptomaticNoneClinical + electrophysiology2Classic sensorimotorCamdessanche et al. \[[@CR11]\]France64M11 days afterUL and LL paraesthesiaAscendent weakness, flaccid tetraparesis, generalized areflexia, dysphagiaNoneYes3 days after symptoms onsetFever (high grade), cough, pneumoniaNoneClinical + CSF + electrophysiology1Classic sensorimotorChan et al. \[[@CR12]\]Canada58M20 days after home isolation for suspected contactBilateral facial weakness, dysarthria, feet paraesthesia, LL areflexiaNANoneNoNAAsymptomatic, interstitial pneumoniaNoneClinical + CSF + electrophysiology1Bilateral facial palsywith paraesthesiaChan et al. \[[@CR13]\]USA68M18 days afterGait disturbance, hands and feet paraesthesiaLL proximal weakness, absent vibratory and proprioceptive sense at the toes, UL hyporeflexia, LL areflexia, unsteady gait with inability to toe or heel walk, bilateral facial weakness, dysphagia, dysarthria, neck flexion weaknessNoneNo8 days after the onset of symptomsFever and upper respiratory symptomsNAClinical + CSF2Classic sensorimotorChan et al. \[[@CR13]\]USA84M16 days afterHands and feet paraesthesia, progressive gait disturbanceBilateral facial weakness, progressive arm weakness, neuromuscular respiratory failureYes (not specified autonomic dysfunction)Yes25 days after the onset of symptomsFeverNAClinical + CSF2Classic sensorimotorCoen et al. \[[@CR14]\]Switzerland70M6 days afterParaparesis, distal allodyniaGeneralized areflexiaDifficulties in voiding and constipationNoNADry cough, myalgia, fatigueNoneClinical + CSF + 0electrophysiology1Classic sensorimotorEbrahimzadeh et al. \[[@CR15]\]Iran46M18 days afterPain and numbness in distal LL and UL extremities, ascending weakness in legsMild peripheral right facial nerve palsy, generalized areflexiaNoneNo7 days after symptoms onsetLow-grade fever, sore thorat, dry cough and mild dyspnea, bilateral interstitial pneumonia (concurrent with neurological symptoms)NoneClinical + CSF + electrophysiology1Classic sensorimotorEbrahimzadeh et al. \[[@CR15]\]Iran65M10 days afterProgressive ascending LL and UL extremities weakness and paraesthesiaProximal and distal UL and LL weakness, UL hyporeflexia and LL areflexiaNoneNo14 days after symptoms onsetHistory of COVID-19 (symptoms not specified), fine crackles in both lungs (concurrent with neurological symptoms)HypertensionClinical + electrophysiology2Classic sensorimotorEl Otmani et al. \[[@CR16]\]Morocco70F3 days afterWeakness and paraesthesia in the 4 limbsTetraparesis, hypotonia, generalized areflexia, bilateral positive Lasègue signNoneNoNADry cough, pneumoniaRheumatoid arthritisClinical + CSF + electrophysiology1Classic sensorimotorEsteban Molina et al. \[[@CR17]\]Spain55F14 days afterParaesthesia and weakness in the 4 limbsLumbar pain, dysphagia, tetraplegia, general areflexia, bilateral facial palsy, lingual and perioral paraesthesiaNoneYes3 days after symptoms onset (48 h after the admission)Fever, dry cough and dyspnoea, pneumoniaDyslipidemiaClinical + CSF + electrophysiology1Classic sensorimotorFarzi et al. \[[@CR18]\]Iran41M10 days afterParaesthesia of the feetTetraparesis, areflexia at the LL and hyporeflexia at the UL, stocking-and-glove hypesthesia and reduced sense of vibration and positionNoneNo7 days after symptoms onsetCough, dyspnea and feverDM type IIClinical + electrophysiology2Classic sensorimotorFernández--Domínguez et al. \[[@CR19]\]Spain74F15 days afterGait ataxia and generalized areflexiaNANANoNARespiratory symptoms (not further detailed)Hypertension and follicular lymphomaClinical + CSF2Miller Fisher variantFinsterer et al. \[[@CR20]\]India20M5 days afterNANANANANANANAClinical + electrophysiology2NAFrank et al. \[[@CR21]\]Brazil15M\> 5 days afterParaparesis, pain in the LLRapidly progressive ascending tetraparesis, areflexiaNANoNAFever, intense sweatingNAClinical + electrophysiology2Classic sensorimotorGigli et al. \[[@CR22]\]Italy53MNAParaesthesia, gait ataxiaNANANANAFever, diarrheaNAClinical + CSF + electrophysiology1NAGutiérrez-Ortiz et al. \[[@CR23]\]Spain50M3 days afterVertical diplopia, perioral paraesthesia, gait ataxiaRight internuclear ophthalmoparesis and right fascicular oculomotor palsy, ataxia, generalized areflexiaNoneNoNAFever, cough, malaise, headache, low back pain, anosmia, ageusiaBronchial asthmaClinical + CSF2Miller Fisher variantGutiérrez-Ortiz et al. \[[@CR23]\]Spain39M3 days afterDiplopia (bilateral abducens palsy)Generalized areflexiaNoneNoNADiarrhea, low-grade feverNoneClinical + CSF2Polyneuritis cranialis (GBS--Miller Fisher Interface)Helbok et al. \[[@CR24]\]Austria68M14 days afterHypoaesthesia and paraesthesia in the LL, proximal weakness, areflexia, stand ataxiaAscending weakness, flaccid tetraparesis, generalized areflexiaNAYes2 days after symptoms onset (24 h after the admission)Fever, dry cough, myalgia, anosmia and ageusia.NoneClinical + CSF + electrophysiology1Classic sensorimotorHutchins et al. \[[@CR25]\]USA21M16 days afterRight-sided facial numbness and weaknessBilateral facial palsy, severe dysarthria, bilateral LL weakness , bilateral UL paraesthesia, areflexiaNANo3 days after symptoms onsetFever, cough, dyspnoea, diarrhea, nausea, headacheHypertension, prediabetes, and class I obesityClinical + CSF + electrophysiology1Bilateral facial palsy with paraesthesiaJuliao Caamaño et al. \[[@CR26]\]Spain61M10 days afterFacial diplegiaNo progressionNoneNo1 day after symptoms onsetFever and coughNoneClinical + electrophysiology3Bilateral facial nerve palsyKhalifa et al. \[[@CR27]\]Kingdom of Saudi Arabia11M20 days afterGait ataxia, areflexia and paraesthesia in the LLGradual motor improvement, persistent hyporeflexiaNANoNAAcute upper respiratory tract infection, low-grade fever, dry cough.NAClinical + CSF + electrophysiology1Classic sensorimotorKilinc et al. \[[@CR28]\]The Netherlands50M24 days afterFacial diplegia, symmetrical proximal weakness, paraesthesia of distal extremities, gait ataxia, areflexiaProgression of limb weakness and inability to walkNANo11 days after symptoms onsetDry coughNoneClinical + electrophysiology2Classic sensorimotorLampe et al. \[[@CR29]\]Germany65M2 days afterAcute right UL and LL weakness causing recurrent fallsRight UL paresis, slight paraparesis more pronounced on the right side, generalized hyporeflexiaNoneNo3 days after symptoms onsetFever and dry coughNoneClinical + CSF + electrophysiology1Pure motorLantos et al. \[[@CR30]\]USA36M4 days afterOpthalmoparesisa and hypoesthesia below kneeProgressive ophthalmoparesis (including initial left III cranial nerve and eventual bilateral VI cranial nerve palsies), ataxia, and hyporeflexiaNoneNoNAFever, chills, and myalgiaNoneClinical3Miller Fisher variantLascano et al. \[[@CR31]\]Switzerland52F15 days after (no resolution of pneumonia)Back pain, diarrhea, rapidly progressive tetraparesis, distal paraesthesiaWorsening of proximal weakness (tetraplegia), generalized areflexia, ataxiaConstipation, abdominal painYes4 days after symptoms onsetDry cough, dysgeusia, cacosmiaNoneClinical + CSF + electrophysiology1Classic sensorimotorLascano et al. \[[@CR31]\]Switzerland63F7 days after (no resolution of pneumonia)Limb weakness, pain on the left calfModerate tetraparesis, LL and left UL areflexia, distal hypoesthesia and paraesthesiaNoneNo5 days after symptoms onsetDry cough, shivering, breathing difficulties, chest pain, odynophagiaDM type 2Clinical + electrophysiology2Classic sensorimotorLascano et al. \[[@CR31]\]Switzerland61F22 days afterLL weakness, dizziness, dysphagiaModerate tetraparesis, bilateral facial palsy, lower limb allodynia, severe hypopallesthesia, areflexia (except for bicipital tendon reflexes)NoneYes4 days after symptoms onsetProductive cough, headaches, fever, myalgia, diarrhea, nausea, vomiting, weight loss, recurrent episodes of transient loss of consciousnessNoneClinical + CSF + electrophysiology1Classic sensorimotorManganotti et al. \[[@CR32]\]Italy50F16 days afterDiplopia and facial paraesthesiaAtaxia, diplopia in vertical and lateral gaze, left upper arm dysmetria, generalized areflexia, mild lower facial defects, and mild hypoesthesia in the left mandibular and maxillary branchNoneYes (concurrent pneumonia)NAFever, cough, ageusia, bilateral pneumoniaNoneClinical + CSF2Miller Fisher variantManganotti et al. \[[@CR33]\]Italy72M18 days afterTetraparesis UL \> LL, LL paraesthesia , generalized areflexia, facial weakness on the right sideNANANoNAFever, dyspnea, hyposmia and ageusiaNAClinical + CSF + electrophysiology1Classic sensorimotorManganotti et al. \[[@CR33]\]Italy72M30 days afterTetraparesis LL \> UL, paraesthesia, global areflexiaNANANoNAFever, cough, dyspnea, hyposmia and ageusiaNAClinical + electrophysiology1Classic sensorimotorManganotti et al. \[[@CR33]\]Italy49F14 days afterOphthalmoplegia, limb ataxia, generalized areflexia, diplopia, facial hypoesthesia, facial weaknessNANANoNAFever, cough, dyspnea, hyposmia and ageusiaNAClinical + CSF + electrophysiology1Miller Fisher variantManganotti et al. \[[@CR33]\]Italy94M33 days afterLL weakness, generalized hyporeflexiaNANANoNAFever, cough, gastrointestinal symptomsNAClinical + electrophysiology2Classic sensorimotorManganotti et al. \[[@CR33]\]Italy76M22 days afterQuadriparesis UL \> LL, generalized areflexia, facial weakness, transient diplopiaNANANoNAFever, cough, dysuria, hyposmia, ageusiaNAClinical + CSF + electrophysiology1Pure motorMarta-Enguita et al. \[[@CR34]\]Spain76F8 days afterBack pain and progressive tetraparesis with distal-onset paraesthesiaProgressive with dysphagia and cranial nerves involvement, generalized areflexiaNAYes10 days after symptom onsetCough and fever without dyspneaNoneClinical3NAMozhdehipanah et al. \[[@CR35]\]Iran38M16 days afterProgressive LL paraesthesia, facial diplegia, lobal areflexiaMild LL weakness , bulbar symptoms developedBlood pressure instability, tachycardiaNo8 days after symptoms onsetUpper respiratory infection (no further details)NAClinical + CSF + electrophysiology1Bilateral facial palsy with paraesthesiaMozhdehipanah et al. \[[@CR35]\]Iran14FNAAscending quadriparesis, UL hyporeflexia, LL areflexia, distal hypoesthesia, ataxiaNANANoNAUpper respiratory infection (no further details)NAClinical + CSF2Classic sensorimotorMozhdehipanah et al. \[[@CR35]\]Iran44F26 days afterWeakness of LLTetraparesis, generalized areflexia, symmetrical hypoesthesiaNAYesNADry cough, fever, myalgia, progressive dyspneaCOPDClinical + CSF + electrophysiology1Classic sensorimotorMozhdehipanah et al. \[[@CR35]\]Iran66F30 days afterProgressive UL and LL weakness, generalized areflexia, symmetrical hypoesthesiaNANoNoNAFever, dry cough, severe myalgiaDM, hypertension, and rheumatoid arthritisClinical + CSF + electrophysiology1Classic sensorimotorNaddaf et al. \[[@CR36]\]USA58F17 days afterProgressive paraparesis, imbalance, severe lower thoracic pain without radiationMild neck flexion weakness, mild/moderate distal UL  and proximal and distal LL  weakness, UL hyporeflexia, LL areflexia, moderately severe length-dependent sensory loss in the feet, ataxic gaitNoneNoNAFever, dysgeusia without anosmia, bilateral interstitial pneumoniaNoneClinical + CSF + electrophysiology1Classic sensorimotorOguz-Akarsu et al. \[[@CR37]\]Turkey53FConcurrent pneumoniaDysarthria, progressive LL weakness and numbnessAtaxia, generalized areflexiaNoneNoNAMild fever (37.5 °C), pneumoniaNoneClinical + electrophysiology2Classic sensorimotorOttaviani et al. \[[@CR38]\]Italy66F7 days after (concurrent pneumonia)Flaccid paraparesis, no sensory symptomsProgressively developed proximal weakness in all limbs, dysesthesia, and unilateral facial palsy, generalized areflexiaNAYes13 days after symptoms onsetFever and cough, pneumoniaNAClinical + CSF + electrophysiology1Classic sensorimotorPadroni et al. \[[@CR39]\]Italy70F23 days afterUL and LL paraesthesia, gait difficulties, astheniaAscendant weakness, tetraparesis, generalized areflexiaNoneYes6 days after symptoms onsetFever (38.5 °C), dry cough, pneumoniaNoneClinical + CSF + Electrophysiology1Classic sensorimotorPaterson et al. \[[@CR40]\]UK42M13 day afterDistal limb numbness and weakness, dysphagiaTetraparesis, generalized areflexia, sensory lossNAYes16 days after symptom onsetCough, fever dyspnea, diarrhea, anosmiaNoneClinical + CSF + electrophysiology1Classic sensorimotorPaterson et al. \[[@CR40]\]UK60M1 day beforeDistal limb numbness and weaknessTetraparesis, generalized areflexia, sensory loss, dysautonomia, facial and bulbar weaknessYesYes5 days after symptom onsetHeadache, ageusia, anosmiaNAClinical + CSF + electrophysiology1Classic sensorimotorPaterson et al. \[[@CR40]\]UK38M21 day afterDistal limb numbness, weakness, clumsinessMild distal weakness, sensory ataxiaNoneNoNACough, diarrheaNAClinical + CSF + electrophysiology1Classic sensorimotorPaybast et al. \[[@CR41]\]Iran38M21 days afterAcute progressive ascending paraesthesia of distal LLQuadriparesthesia, bilateral facial droop with drooling of saliva and slurred speech, generalized areflexia, swallowing inability, bilaterally absent gag reflexTachycardia and blood pressure instabilityNo3 days after symptoms onsetSymptoms of upper respiratory tract infectionHypertensionClinical + CSF + electrophysiology1Classic sensorimotorPaybast et al. \[[@CR41]\]Iran14F21 days afterProgressive ascending quadriparesthesia, mild LL weaknessMild proximal and distal LL weakness, hypoactive deep tendon reflexes in UL and absent in LL, decreased light touch, position, and vibration sensation in all distal limbs up to ankle and elbow joints, gait ataxiaNoneNo2 days after symptoms onsetSymptoms of upper respiratory tract infectionNoneClinical + CSF2Classic sensorimotorPfefferkorn et al. \[[@CR42]\]Germany51M14 days afterUL and LL weakness, acral paraesthesiaTetraparesis, generalized areflexia, deterioration to an almost complete peripheral locked-in syndrome with tetraplegia, complete sensory loss at 4 limbs, bilateral facial and hypoglossal paresisNoneYes15 days after symptoms onsetFluctuating fever, flu-like symptoms with marked fatigue and dry cough, pneumoniaNAClinical + CSF + electrophysiology1Classic sensorimotorRana et al. \[[@CR43]\]USA54M14 days afterLL paresthesias of LLAscending tetraparesis, general areflexia, burning sensation diplopia, facial diplegia, mild ophthalmoparesisResting tachycardia and urinary retentionYesNARhinorrhea, odynophagia, fever, chills, and night sweatsHypertension, hyperlipidemia, restless leg syndrome, and chronic back pain, concurrent *C. Difficile* infectionClinical + electrophysiology2Miller Fisher variantReyes-Bueno et al. \[[@CR44]\]Spain50F15 days afterRoot-type pain in all four limbs, dorsal and lumbar back painLL Weakness, ataxia, diplopia, bilateral facial palsy, generalized areflexiaDry mouth, diarrhea and unstable blood pressureNo12 days after symptoms onsetDiarrhea, odynophagia and coughNAClinical + CSF + electrophysiology1Miller Fisher variantRiva et al. \[[@CR45]\]Italy60+M17 days afterProgressive limb weakness and distal paresthesia at four limbsAscending paraparesis with involvement of the cranial nerves (facial diplegia), generalized areflexiaNoneNo10 days after symptoms onsetFever, headache, myalgia, anosmia and ageusiaNAClinical + electrophysiology2Classic sensorimotorSancho-Saldaña et al. \[[@CR46]\]Spain56F15 days afterUnsteadiness and paraesthesia in both handsLumbar pain and ascending weakness, global areflexia, bilateral facial nerve palsy, oropharyngeal weakness and severe proximal tetraparesisNoYes3 days after symptoms onsetFever, dry cough and dyspnea, pneumoniaNAClinical + CSF + electrophysiology1Classic sensorimotorScheidl et al. \[[@CR47]\]Germany54F11 days afterProximal weakness of LL, numbness of 4 limbsInitial worsening of the paraparesis with rapid improvement upon initiation of the treatment, areflexiaNoneNo12 days after symptoms onsetTemporary ageusia,NoneClinical + CSF + electrophysiology1Paraparetic variantSedaghat et al. \[[@CR48]\]Iran65M14 days afterLL distal weaknessAscending weakness, tetraparesis, facial bilateral palsy, generalized areflexia, LL distal hypoesthesia and hypopallesthesiaNoneNo4 days after symptoms onsetFever, cough and sometimes dyspnea, pneumoniaDM type 2Clinical + electrophysiology2Classic sensorimotorSidig et al. \[[@CR49]\]Sudan65M5 days afterNumbness and weakness in both UL and LLAscending weakness, bilateral facial paraesthesia and palsy, clumsiness of UL, tetraparesis, slight palatal muscle weakness, areflexiaUrinary incontinenceYesNALow-grade fever, sore throat, dry cough, headache and generalized fatigabilityDM and HypertensionClinical + electrophysiology2Classic sensorimotorSu et al. \[[@CR50]\]USA72M6 days afterProximal UL and LL weaknessProgression with worsening of the paresis, areflexia, hypoesthesiaHypotension alternating with hypertension and tachycardiaYes8 days after symptoms onsetMild diarrhea, anorexia and chills without fever or respiratory symptomsCoronary artery disease, hypertension and alcohol abuseClinical + CSF + electrophysiology1Classic sensorimotorTiet et al. \[[@CR51]\]United Kingdom49M21 days afterDistal LL paraesthesiaLL and UL weakness, facial diplegia, distal reduced sensation to pinprick and vibration sense, LL dysesthesia, generalized areflexiaNoneNo4 days after symptoms onsetShortness of breath, headache and coughSinusitisClinical + CSF + electrophysiology1Classic sensorimotorToscano et al. \[[@CR52]\]Italy77F7 days afterUL and LL paraesthesiaFlaccid tetraplegia, areflexia, facial weakness, dysphagie, tongue weaknessNoneYesNAFever, cough, ageusia, pneumoniaPrevious ischemic stroke, diverticulosis, arterial hypertension, atrial fibrillationClinical + CSF + electrophysiology1Classic sensorimotorToscano et al. \[[@CR52]\]Italy23M10 days afterFacial diplegiaLL paraesthesia, generalized areflexia, sensory ataxiaNoneNo2 days after symptoms onsetFever, pharyngitisNAClinical + CSF + electrophysiology1Bilateral facial palsy with paraesthesiaToscano et al. \[[@CR52]\]Italy55M10 days afterNeck pain, Paresthesias in the 4 limbs, LL weaknessFlaccid tetraparesis, areflexia, facial weaknessNoneYesNAFever, cough, pneumoniaNAClinical + CSF + electrophysiology1Classic sensorimotorToscano et al. \[[@CR52]\]Italy76M5 days afterLumbar pain, LL weaknessFlaccid tetraparesis, generalized areflexia, ataxiaNoneNo4 days after symptoms onsetCough and hyposmiaNAClinical + CSF+Electrophysiology1Classic sensorimotorToscano et al. \[[@CR52]\]Italy61M7 days afterLL weakness and paraesthesiaAscending weakness, tetraplegia, facial weakness, areflexia, dysphagiaNoneYesNACough, ageusia and anosmia, pneumoniaNAClinical + CSF+ electrophysiology1Classic sensorimotorVelayos Galán et al. \[[@CR53]\]Spain43M10 days afterDistal weakness and numbness of the 4 limbs, gait ataxiaProgression of the weakness with bilateral facial paresis and dysphagia, generalized areflexiaNANo2 days after admissionCough, pneumoniaNAClinical + electrophysiology2Classic sensorimotorVirani et al. \[[@CR54]\]USA54M8 days afterLL weakness, numbnessAscending weakness, tetraparesis, areflexiaUrinary retentionYesShortly after presentation in the outpatient clinic (after 2 days of symptoms onset)Fever (102 F), dry cough, pneumonia*Clostridium difficile* colitis 2 days before GBS onsetClinical3Classic sensorimotorWebb et al. \[[@CR55]\]United Kingdom576 days afterAtaxia, progressive limb weakness and foot dysaesthesia,Tetraparesis, generalized areflexia, hypoesthesia in the 4 limbs, hypopallesthesia in LL, dysphagiaNoneYes3 days after symptoms onsetMild cough and headache, myalgia and malaise, slight fever, diarrhea, pneumoniaUntreated hypertension and psoriasisClinical + CSF + electrophysiology1Classic sensorimotorZhao et al. \[[@CR56]\]China61F8 days beforeLL weaknessAscending weakness, tetraparesis, areflexia, LL distal hypoesthesiaNoneNo4 days after symptoms onsetFever (38·2 °C), dry cough pneumoniaNAClinical + CSF + electrophysiology1Classic sensorimotorArticleCOVID-19 diagnosisBlood findingsAuto-antibodies and screening for most common GBS causesCSF findingsElectrophysiology: Neuropathy type and GBS electrophysiologic subtypeMRI (brain and spinal)Management and therapyOutcomeGBSCOVID-19Agosti et al. \[[@CR5]\]RT-PCR + chest CTThrombocytopenia (101 × 10^9^ /L, reference value: 125--300 × 10^9^ /L), lymphocytopenia (0.48 × 10^9^ /L, reference value: 1.1--3.2 × 10^9^ /L)Negative ANA, anti-DNA, c-ANCA, p-ANCA, negative screening for *Campylobacter jejuni*, *Mycoplasma pneumoniae*, *Salmonella enterica*, CMV, HSV 1 and 2, VZV, influenza virus A and B, HIV, normal B12 and serum protein electrophoresisIncreased total protein (98 mg/dl), cell count: 2/10^6^ LDemyelinatingAIDPNAIVIG 400 mg/kg/day (5 days)Antiviral drugs (not specifically mentioned)Improvement, discharged home after 30 daysAlberti et al. \[[@CR6]\]RT-PCR + chest CTNANAIncreased total protein (54 mg/dl), 9 cells/µl, negative SARS-CoV-2 PCRDemyelinatingAIDPNAIVIG 400 mg/kg (5 days) + mechanical invasive ventilationLopinavir/ritonavir, hydroxychloroquine24 h after admission, death because of respiratory failureArnaud et al. \[[@CR7]\]RT-PCR + chest CTNANegative anti-ganglioside and antineural antibodies, negative *Campylobacter Jejuni*, HIV, syphilis, CMV, EBV serologyIncreased total protein (1.65 g/L), no pleyocitosis, negative oligoclonal bands, negative SARS-CoV-2 PCR, negative EBV and CMV RT-PCRDemyelinatingAIDPNAIVIG 400 mg/kg (5 days)Hydroxychloroquin, cefotaxime, azithromycineProgressive improvementAssini et al. \[[@CR8]\]RT-PCRLymphocytopenia, increased LDH and inflammation markers; low serum albumin (2.9 mg/dL)NANormal total protein level, increased IgG/albumin ratio (233), negative SARS-CoV-2 PCR, presence of oligoclonal bands (both in serum and CSF)Demyelinating with sural sparingAIDPBrain: no pathological findingsIVIG 400 mg/kg (5 days)Hydroxychloroquine, arbidol, ritonavir and lopinavir + mechanical invasive ventilation5 days after IVIG, improvement of swallowing, speech, tongue motility, eyelid ptosis and strengthAssini et al. \[[@CR8]\]RT-PCR + chest CTLymphocytopenia, increased LDH and GGT, leucocytosis, low serum albumin (2.6 mg/dL)Negative anti-ganglioside antibodiesNormal total protein level, increased IgG/albumin ratio (170), negative SARS-CoV-2 PCR, presence of oligoclonal bands (both in serum and CSF)Motor sensory axonal, muscular neurogenic changesAMSANNAIVIG 400 mg/kg (5 days)Hydroxychloroquine, antiretroviral therapy, tocilizumab + tracheostomy and assisted ventilation5 days after IVIG, improvement of vegetative symptoms, persistence of hyporeflexia and right foot dropBigaut et al. \[[@CR9]\]RT-PCR + chest CTNormal blood count, negative CRPNegative anti-ganglioside antibodies, negative HIV, Lyme and syphilis serologyIncreased total protein (0.95 g/L), cell count: 1 × 10^6^/L, negative SARS-CoV-2 PCRDemyelinatingAIDPSpinal: Radiculitis and plexitis on both brachial and lumbar plexus; multiple cranial neuritis (in III, VI, VII, and VIII nerves)IVIG 400 mg/kg (5 days) + non-invasive ventilationNAProgressive improvementBigaut et al. \[[@CR9]\]RT-PCR + chest CTIncreased CRPNegative anti-ganglioside antibodiesIncreased total protein (1.6 g/L), cell count: 6 × 10^6^/L, negative SARS-CoV-2 PCRDemyelinatingAIDPNAIVIG 400 mg/kg (5 days)NASlow progressive improvementBracaglia et al. \[[@CR10]\]RT-PCR (normal chest CT)Elevated CPK (461 U/L, normal \< 145), CRP 5,65 mg/dL (normal \< 0.5), lymphocyto- penia (0·68 × 10^9^/L, normal 1·10^--4^), mild increase of LDH (284 U/L, normal \< 248), GOT and GPT (549 and 547 U/L, normal \< 35), elevation of IL-6 (11 pg/mL, normal \< 5.9)Negative anti-ganglioside antibodies; negative microbiologic testing on CSF and serum for HSV1-2, EBV, VZV, CMV, HIV, Mycoplasma Pneumoniae and Borrelia.Increased total protein (245 mg/dL) and increased cell count: 13 cells/mm^3^, polymorphonucleate 61.5%DemyelinatingAIDPNAIVIG 400 mg/kg (5 days)Hydroxychloroquine, ritonavir, darunavirImprovement of UL and LL weakness, development of facial diplegiaCamdessanche et al. \[[@CR11]\]RT-PCR + chest CTNANegative anti-gangliosides antibodies; negative screening for *Campylobacter jejuni, Mycoplasma pneumoniae*, Salmonella enterica, CMV, EBV, HSV1-2, VZV, Influenza virus A & B, HIV, and hepatitis EIncreased total protein (1.66 g/L), normal cell countDemyelinatingAIDPNAIVIG 400 mg/kg (5 days) + mechanical invasive ventilationOxygen therapy, paracetamol, low molecular weight heparin, lopinavir/ritonavir 400/100 mg twice a day for 10 daysNAChan et al. \[[@CR12]\]RT-PCR + chest CTPersistent thrombocytosis (maximum PC 688 ×10^9^/L), elevated [d]{.smallcaps}-dimer (1.47 mg/L)NAIncreased total protein (1.00 g/L), cell count: 4 × 10^6^/L (normal), negative SARS-CoV-2 PCRDemyelinatingAIDPBrain: bilateral intracranial facial nerve enhancementIVIG 400 mg/kg (5 days)Empiric azithromycin and ceftriaxoneSlight improvement of facial weakness, unchanged paraesthesiaChan et al. \[[@CR13]\]RT-PCRNANegative anti-gangliosides antibodiesIncreased total protein (226 mg/dL), leucocytes: 3 cells/mm^3^, glucose: 56 mg/dL, negative SARS-CoV-2 PCRNALumbosacral spine: no pathological findings5 sessions of plasmapheresisNAResolution of dysphagia, ambulation with minimal assistance 28 days after symptoms onsetChan et al. \[[@CR13]\]RT-PCRNAElevated GM2 IgG/IgM antibodiesIncreased total protein (67 mg/dL), leucocytes: 1 cells/mm^3^, glucose 58 mg/dL, negative SARS-CoV-2 PCRNANAMechanical invasive ventilation + 5 sessions of plasmapheresis (without benefit on ventilation) + IVIGNAPersistence of quadriparesis with intermittent autonomic dysfunction, slowly weaned from the ventilatorCoen et al. \[[@CR14]\]RT-PCR + serologyNormal (not specified)Negative anti-gangliosides antibodies; negative meningitis/encephalitis panelAlbuminocytological dissociation, no intrathecal IgG synthesis, negative SARS-CoV-2 PCRDemyelinating with sural sparingAIDPBrain: NASpinal: no pathological findingsIVIG 400 mg/kg (5 days)NARapid improvement. From day 11 from hospitalisationRehabilitationEbrahimzadeh et al. \[[@CR15]\]RT-PCR + chest CTNormal CRP (5 mg/L), normal serum protein immunoelectrophoresisNegative anti-GQ1b antibodies, negative screening for *Campylobacter jejuni*, HIV, EBV, CMV, influenza virus (type A and B), HCV, non-reactive VDRLIncreased total protein (78 mg/dL), normal cell count (erythrocyte = 0/mm^3^, leukocyte = 4/mm^3^), normal glucose (70 mg/dL)DemyelinatingAIDPBrain: no pathological findingsSpinal: no pathological findingsNoneHydroxychloroquine for 5 daysImprovement of muscle strength to near normal after 16 daysEbrahimzadeh et al. \[[@CR15]\]RT-PCR + chest CTSlightly elevated CRP (34 mg/L), normal serum protein immunoelectrophoresisNegative anti-GQ1b antibodies, negative screening for *Campylobacter jejuni*, HIV, EBV, CMV, influenza virus (type A and B), HCV, non-reactive VDRLNADemyelinatingAIDPNAIVIGNAImprovement of muscle strength in all extremities after 14 daysEl Otmani et al. \[[@CR16]\]RT-PCR + chest CTLymphocytopenia (520/ml)NAIncreased total protein (1 g/L), normal cell count, negative PCR assay forSARS-CoV-2Motor sensory axonalAMSANNAIVIG 400 mg/kg/day (5 days)Hydroxychloroquine 600 mg/day; azithromycin 500 mg at the first day, then 250 mg per dayAt week 1 from admission no significant neurological improvementEsteban Molina et al. \[[@CR17]\]RT-PCR + chest X-rayLeucocyte 7400/mm^3^, lymphocyte 2400/mm^3^. Hb 14 g/dl. PC 408,000/mm^3^, [d]{.smallcaps}-Dimer 556 ng/ml. Ferritin 544 ng/ml, CRP 2.04 mg/dl, Fibrinogen 6.8 g/dlNegative bacteriological and viral testsIncreased total protein (86 mg/dL), cell count: 3x10^6^/LDemyelinatingAIDPBrain: leptomeningeal enhancement in midbrain and cervical spineIVIG 400 mg/kg/day (5 days)Hydroxychloroquine, azithromycin, ceftriaxonMotor improvement but persistence of paraesthesiaFarzi et al. \[[@CR18]\]RT-PCR + chest CTLymphopenia (WBC:5.9 × 10^9^/L, neutrophils: 85%, lymphocyte:15%), elevated levels of CRP, ESR 69 mm/hNANADemyelinatingAIDPNAIVIG (2 g/kg over 5 days)Lopinavir/ritonavir and hydroxychloroquineImprovement after 3 days, favorable outcomeFernández--Domínguez et al. \[[@CR19]\]RT-PCRNANegative anti-GD1b antibodies, negative other anti-ganglioside antibodiesIncreased total protein (110 mg/dL), albuminocytological dissociationDemyelinatingNABrain: no pathological findingsIVIG 20 g/day (5 days)Hydroxychloroquine, lopinavir/ritonavirNAFinsterer et al. \[[@CR20]\]NANANANAAxonalAMANNAIVIGNARecoveryFrank et al. \[[@CR21]\]RT-PCR, + serology (IgG and IgM)WBC and CRP normalNegative hepatitis B and C, HIV and VDRL testsTwo CSF analysis 2 weeks apart, both showing normal cell count and CSF biochemistry, negative SARS-CoV-2 PCR, negative PCR for HSV1, HSV2, CMV, EBV, VZV; Zika virus; Dengue virus and Chikungunya virusAxonalAMANBrain: no pathological findingsSpinal: no pathological findingsIVIG 400 mg/kg/day (5 days)Methylprednisolone, azithromycin, albendazoleSome improvement, weakness persistedGigli et al. \[[@CR22]\]Chest CT + serology (negative RT-PCR)NANegative anti-ganglioside antibodies, negative PCR for influenza A and B viruses (nasal swab)Increased total protein (192.8 mg/L), leucocytes: 2.6 cells/µL, positive Ig for SARS-CoV-2, negative SARS-CoV-2 PCRDemyelinatingAIDPNANANANAGutiérrez-Ortiz et al. \[[@CR23]\]RT-PCRLymphocytes 1000 cells/UI, CRP 2.8 mg/dlPositive anti-GD1b antibodies, other anti-ganglioside antibodies negativeIncreased total protein (80 mg/dl), no leucocytes, glucose62 mg/dl, negative SARS-CoV-2 PCRNANAIVIG 400 mg/kg (5 days)NAAfter 2 weeks from admission complete resolution except anosmia, ageusiaGutiérrez-Ortiz et al. \[[@CR23]\]RT-PCRLeucopenia (3100 cells/µl)NAIncreased total protein (62 mg/dl), WBC: 2/μl (all monocytes), glucose: 50 mg/dl, negative SARS-CoV-2 PCRNANANoneParacetamol2 weeks later complete neurological recovery with no ageusia, complete eye movements, and normal deep tendon reflexesHelbok et al. \[[@CR24]\]Chest CT + serology (repeated negative RT-PCR)WBC 8.1G/L (normal: 4.0--10.0G/L), CRP 2.3 mg/dL, (normal: 0.0--0.5 mg/dL), fibrinogen level 650 mg/dL (normal: 210--400 mg/dL), LDH 276 U/L (normal: 100--250 U/L), erythrocyte sedimentation rate 55 mm/1 hNegative PCR for CMV, EBV, influenza virus A/B, Respiratory Syncytial Virus and IgM antibodies for *Chlamydia pneumoniae* and *Mycoplasma pneumoniae*Increased total protein (64 mg/dl), cell count: 2 cells/mm^3^, serum/ CSF glucose ratio of 0.83, negative SARS-CoV-2 PCR, positive anti-SARS-CoV-2 antibodies (not determined if intrathecal synthesis or passive transfer from blood)Demyelinating with sural sparingAIDPSpinal: no pathological findingsIVIG 30 g + plasma exchange (4 cycles) + mechanical invasive ventilationNoneImprovement of muscle forces with recovery of mobility without significant help after 8 weeksHutchins et al. \[[@CR25]\]RT-PCR + chest CTLymphopenia (absolute lymphocyte count of 0.7 K/mm^3^)Serum HSV IgG and IgM. Respiratory viral panel PCR negative Negative GM1, GD1b, and GQ1b IgG and IgM), aquaporin-4 receptor (IgG), HIV 1/2, HSV 1/2 (IgG and IgM), CMV (IgM), *Mycoplasma pneumoniae* (IgG and IgM), *Borrelia burgdorferi* (IgG and IgM), *Bartonella* species (IgG and IgM), and syphilis (Venereal Disease Research Laboratory test)Increased total protein (49 mg/dL), normal glucose levels (65 mg/dL), no leukocytesMixed demyelinating and axonal EMG subtype unknownBrain: enhancement of the facial and abducens nerves bilaterally, as well as the right oculomotor nerveSpinal: no pathological findingsPlasma exchange (5 cycles)NADischarged to inpatient rehabilitationJuliao Caamaño et al. \[[@CR26]\]RT-PCRNANANormal total protein (44 mg/dL), no pleocytosisAbsent blink-reflexEMG subtype unknownBrain: no pathological findingsOral prednisoloneHydroxychloroquine and lopinavir/ritonavir for 14 daysMinimal improvement of muscle weakness after 2 weeksKhalifa et al. \[[@CR27]\]RT-PCR + chest X-ray + chest CTWBC 5.5 × 10^3^, PC 356 × 10^3^, CRP 0.5 mg/dL (normal 0.0--0.5), serum ferritin 87.3 ng/ml (normal 12.0--150.0), elevated [d]{.smallcaps}-Dimer levels 0.72 mg/L (0.00--0.49)Negative screening for:  influenza A and B viruses; influenza A virus subtypes H1, H3, and H5 including subtype H5N1 of the Asian lineage; parainfluenza virus types 1, 2, 3, and 4; respiratory syncytial virus types A and B; adenovirus; metapneumovirus; rhinovirus; enterovirus; Coronavirus 229E, HKU1, NL63, and OC43Cell count: 5 mm^3^, increased total protein (316.7 mg/dL)DemyelinatingAIDPBrain: no pathological findingsSpinal: enhancement of the cauda equina nerve rootsIVIG 1 g/kg (2 days)Paracetamol, azithromycin, hydroxychloroquineDischarge to home after 15 days with clinical and electrophysiological improvementKilinc et al. \[[@CR28]\]Fecal PCR + serologyNANegative anti-GQ1b antibodies, serologic tests on *Borrelia burgdorferi*, syphilis, *Campylobacter jejuni*, CMV, hepatitis E, *Mycoplasma pneumoniae* and CMVNormal cell count, normal proteinsPredominantly demyelinatingAIDPBrain: no pathological findingsIVIG 2 g/kg (5 days)NonePersistence of mild symptoms at the discharge (after 14 days)Lampe et al. \[[@CR29]\]RT-PCR (negative chest X-ray)Slightly increased CRP (1.92 mg/dL)Negative anti-ganglioside antibodies; negative influenza and respiratory syncytial virusIncreased total protein (56 mg/dL), normal cell count (2 cells/μL)DemyelinatingAIDPNAIVIG 400 mg/kg (5 days)NoneImprovement of GBS symptoms with persistence of generalized areflexia except for left biceps reflex, discharge after 12 daysLantos et al. \[[@CR30]\]RT-PCRNAGM1 antibodies in the equivocal rangeNANABrain: enlargement, prominent enhancement with gadolinium, and T2 hyperintense signal of the left cranial nerve IIIIVIGHydroxychloroquineImprovement, discharge after 4 daysLascano et al. \[[@CR31]\]RT-PCR + chest X-ray + positive IgM (IgG positivity 2 weeks later)WBC 8900 cells/mm^3^; lymphocytes 1200 cells/mm^3^; PC 45,500 cells/mm^3^Negative anti-ganglioside antibodiesIncreased total protein (60 mg/dL), leucocytes: 3 cells/μL, negative SARS-CoV-2 PCRDemyelinatingAIDPSpinal: no nerve root gadolinium enhancementIVIG 400 mg/kg (5 days) + mechanicalinvasive ventilationAzithromycinImprovement of tetraparesis.Able to stand up with assistance.Lascano et al. \[[@CR31]\]RT-PCR + chest X-rayWBC 3300 cells/mm^3^; lymphocytes 800 cells/mm^3^; PC 119,000 cells/mm^3^NANormal total protein (40 mg/dl), cell count: 2 cells/μLMixed demyelinating (conduction blocks) and axonal with sural sparing patternPredominantly AIDPNAIVIG 400 mg/kg (5 days)Amoxicillin, clarithromycinDismissal with full motor recovery. Persistence of LL areflexia and distal paraesthesiaLascano et al. \[[@CR31]\]RT-PCR + chest X-rayWBC 4000 cells/mm^3^; lymphocytes 600 cells/mm^3^; PC 322,000 cells/mm^3^NAIncreased total protein (140 mg/dL), cell count: 4 cells/μL, negative SARS-CoV-2 PCRDemyelinating with sural sparing patternAIDPBrain: no pathological findingsSpinal cord: lumbosacral nerve root enhancementIVIG 400 mg/kg (5 days)AmoxicillinImprovement of tetraparesis and ability to walk with assistance. Persistence of neuropathic pain and distal paraesthesiaManganotti et al. \[[@CR32]\]RT-PCR + chest CTNANegative anti-ganglioside antibodies negative serum anti-HIV, anti-HBV, anti-HCV antibodiesIncreased total protein (74.9 mg/dL), negative CSF PCR for bacteria, fungi, *Mycobacterium tuberculosis*, Herpes viruses, Enteroviruses, Japanese B virus and Dengue virusesNABrain: no pathological findingsIVIG 400 mg/kg (5 days)Lopinavir/ritonavir, hydroxychloroquine, antibiotic therapy, oxygen support (35%)Resolution of all symptoms except for minor hyporeflexia at the LLManganotti et al. \[[@CR33]\]RT-PCRIL-1: 0.2 pg/ml (\< 0.001 pg/ml), IL-6: 113.0 pg/ml (0.8--6.4 pg/ml), IL-8: 20.0 pg/ml (6.7--16.2 pg/ml), TNF-α: 16.0 pg/ml (7.8--12.2 pg/ml)Negative anti-ganglioside antibodies, negative HIV, HBV, HCV negative serological tests for autoimmune disordersIncreased total protein (52 mg/dl), leucocytes: 1 cell/mm^3^, negative SARS-CoV-2 PCRDemyelinatingAIDPNAIVIG 400 mg/kg/day (5 days)Hydroxychloroquine, oseltamivir, darunavir, methylprednisolone and tocilizumab + mechanical invasive ventilationImprovement of motor symptomsManganotti et al. \[[@CR33]\]RT-PCRIL-1: 0.5 pg/ml (\< 0.001 pg/ml), IL-6: 9.8 pg/ml (0.8--6.4 pg/ml), IL-8: 55.0 pg/ml (6.7--16.2 pg/ml), TNF- α: 16.0 pg/ml (7.8--12.2 pg/ml)Negative anti-ganglioside antibodies, negative HIV, HBV, HCV negative serological tests for autoimmune disordersNormal total protein (40 mg/dl), leucocytes: 1 cell/mm^3^, negative SARS-CoV-2 PCRMixed demyelinating and axonal   EMG subtype unknownBrain: no pathological findingsIVIG 400 mg/kg/day (5 days)Hydroxychloroquine, lopinavir/ritonavir, methylprednisolone + mechanical invasive ventilationImprovement of motor symptomsManganotti et al. \[[@CR33]\]RT-PCRNANegative anti-ganglioside antibodies, negative HIV, HBV, HCV negative serological tests for autoimmune disordesIncreased total protein (72 mg/dL), leucocytes: 5 cell/mm^3^, negative SARS-CoV-2 PCRMainly demyelinatingPredominantly AIDPBrain: no pathological findingsIVIG 400 mg/kg/day (5 days)Hydroxychloroquine, lopinavir/ritonavir, methylprednisoloneImprovementManganotti et al. \[[@CR33]\]RT-PCRNANANAMixed demyelinating and axonal  EMG subtype unknownNAMethylprednisolone 60 mg for 5 daysMethylprednisoloneStationaryManganotti et al. \[[@CR33]\]RT-PCRIL-1: 0.2 pg/ml (\< 0.001 pg/ml), IL-6: 32.7 pg/ml (0.8--6.4 pg/ml), IL-8: 17.8 pg/ml (6.7--16.2 pg/ml), TNF- α : 11.1 pg/ml (7.8--12.2 pg/ml), IL-2R: 1203.0 pg/ml (440.0--1435.0 pg/ml), IL-10: 4.6 (1.8--3.8 pg/ml)Negative anti-ganglioside antibodies, negative HIV, HBV, HCV negative serological tests for autoimmune disordesIncreased total protein (53 mg/dL), leucocytes: 2 cell/mm^3^, negative SARS-CoV-2 PCRMixed demyelinating and axonal  EMG subtype unknownNAIVIG 400 mg/kg/day (5 days)Hydroxychloroquine, lopinavir/ritonavir, methylprednisolone, meropenem, linezolid, clarithromycin, fluconazole, doxycycline + mechanical invasive ventilationImprovementMarta-Enguita et al. \[[@CR34]\]RT-PCR + chest CTThrombocytopenia, [d]{.smallcaps}-Dimer elevationNANANANANANADeath after 10 daysMozhdehipanah et al. \[[@CR35]\]RT-PCR (negative chest CT)Normal WBC, CRP and ESRNAIncreased total protein (139 mg/dL), normal cell count, negative CSF HSV serology and gram stain and cultureDemyelinatingAIDPNAPlasma exchange (5 cycles)NASignificant improvement of muscle weakness after 3 weeks, persistence of mild bifacial paresisMozhdehipanah et al. \[[@CR35]\]RT-PCRNormal WBC, CRP and ESRNAAlbuminocytological dissociationNANAIVIG 400 mg/kg/day (5 days)NAComplete recovery, except for the persistence of hyporeflexiaMozhdehipanah et al. \[[@CR35]\]RT-PCR + chest CTLeucocytosis lymphopenia, elevated ESR and CRPNAIncreased total protein (57 mg/dL), normal cell count and glucose (not further specified)AxonalAMSANNAIVIG 400 mg/kg/day (3 days)Hydroxy chloroquine, lopinavir/ ritonavirDeath after 3 days from starting treatment with IVIGMozhdehipanah et al. \[[@CR35]\]RT-PCR + chest CTLeucocytosis, lymphopenia, elevated ESR and CRPNAIncreased total protein (89 mg/dL), normal cell count and glucose (not further specified)DemyelinatingAIDPNAIVIG 400 mg/kg/day (5 days)Hydroxy chloroquine, lopinavir/ ritonavirNo significant clinical improvementNaddaf et al. \[[@CR36]\]Positive SARS-CoV-2 IgG (index value: 8.2, normal \< 0.8) and IgA + chest CT (negative RT-PCR)Normal completed blood count, elevated [d]{.smallcaps}-dimer (690 ng/mL), ferritin (575 mcg/L), ESR (26 mm/h), alanine aminotransferase (73 U/L)Negative anti-ganglioside antibodies negative HIV, syphilis, West Nile virus, Lyme disease testing, EBV and CMV serology consistent with remote infection, negative paraneoplastic evaluationIncreased total protein (273 mg/dL), total cells count: 2/mm3, negative CSF SARS-CoV-2 RT-PCR, negative meningitis/encephalitis panel, negative oligoclonal bands and IgG indexDemyelinatingAIDPSpine: smooth enhancement of the cauda equine rootsPlasma exchange (5 sessions)Hydroxy chloroquine, zinc, methylprednisolone 40 mg bid for 5 daysImprovement of motor and gait examination. Persistence of slight ataxia without requiring gait aidOguz-Akarsu et al. \[[@CR37]\]RT-PCR + chest MRT + chest CTMild neutropenia (1.49 cells/µL) and a high monocyte percentage (19.77)HIV test negativeNormal total protein (32.6 mg/dL) with no leucocytesDemyelinating with sural sparing patternAIDPCervical and lumbar and spine: asymmetrical thickening and hyperintensity of post-ganglionic roots supplying the brachial and lumbar plexuses in STIR sequencesPlasma exchange (five sessions, one every other day)Hydroxychloroquine, azithromycinMarked neurological improvement after 2 weeks and she was able to walk without assistanceOttaviani et al. \[[@CR38]\]RT-PCR + chest CTLymphopenia, increased [d]{.smallcaps}-dimer, CRP and CKNegative anti-ganglioside antibodiesIncreased total protein (108 mg/dL), cell count: 0 cells/μLMainly demyelinatingPredominantly AIDPNAIVIG 400 mg/kg (5 days)Lopinavir/ritonavir, hydroxychloroquineProgressive worsening with multi-organ failurePadroni et al. \[[@CR39]\]RT-PCR + chest CTWBC 10.41 × 10^9^/L (neutrophils 8.15 × 10^9^/L), normal [d]{.smallcaps}-dimerNegative screening for *Mycoplasma pneumonia*, CMV, *Legionella pneumophila*, *Streptococcus pneumoniae*, HSV, VZV, EBV, HIV-1, *Borrelia burgdorferi*; auto-antibodies not performedIncreased total protein (48 mg/dl), cell count: 1 × 10^6^/LMotor sensory axonalAMSANNAIVIG 400 mg/kg (5 days) + mechanical invasive ventilationNAAt day 6 from admission: ICU with mechanical invasive ventilationPaterson et al. \[[@CR40]\]Definite diagnosis (not specified) (normal chest CT)Increased neutrophils and CRPNAIncreased total protein (0.5 g/L),leucocytes: 3 cells/μL (0--5),DemyelinatingAIDPNAIVIG + mechanical invasive ventilationNone17 days of hospitalisation, at discharge able to walk 5 m (across an open space) but incapable of manual work/runningPaterson et al. \[[@CR40]\]Definite diagnosis (not specified) (normal chest CT)Increased CRP and fibrinogenNAIncreased total protein (0.6 g/L)leucocytes: 2 cells/μL (0-5), Glucose 3.4 (mmol/L; 2.2-4.2)DemyelinatingAIDPBrain: no pathological findingsIVIGMechanical invasive ventilation46 days (ongoing) of hospitalisation, still critical and requiring ventilationPaterson et al. \[[@CR40]\]Definite diagnosis (not specified) (normal chest CT)Not significant findingsNAIncreased total protein (0.9 g/L)leucocytes: \< 1 cells/μL (0-5), Glucose 3.7 (mmol/L; 2.2-4.2)DemyelinatingAIDPBrain: no pathological findingsIVIGNA7 days (ongoing) of hospitalisation, able to walk 5 m (across an open space) but incapable of manual work/runningPaybast et al. \[[@CR41]\]RT-PCRNANAIncreased total protein (139 mg/dL), normal glucose and cell count, normal CSF viral serology, negative gram stain and cultureMixed demyelinating and axonal  EMG subtype unknownNA5 sessions of therapeutic plasma exchange, intravenous bolus of labetalol to control sympathetic nervous system over-reactivityHydroxychloroquine sulphate 200 mg two times per day for a weekPersistence of generalized hyporeflexia, decreased light touch sensation in distal limbs, mild bilateral facial paresis, sympathetic over-reactivity successfully controlled with labetalol,Paybast et al. \[[@CR41]\]RT-PCRNANAAlbuminocytological dissociationNANAIVIG 20 g (5 days)Hydroxychloroquine sulphate 200 mg two times per day for a weekPersistence of generalized hyporeflexia and decreased light touch sensation in distal limbsPfefferkorn et al. \[[@CR42]\]RT-PCR + chest CTNANegative anti-gangliosides antibodiesAt admission: Normal total protein, cell count: 9/µL, negative SARS-CoV-2 PCRAt day 13th: increased total protein (10.231 mg/L), normal cell countDemyelinatingAIDPSpinal: massive symmetrical contrast enhancement of the spinal nerve roots at all levels of the spine including the cauda equina. Anterior and posterior nerve roots were equally affectedIVIG 30 g (5 days) + mechanical invasive ventilation + plasma exchangeNAAt day 31 from admission: motor improvement with regression of facial and hypoglossal paresis but still needed mechanical ventilationRana et al. \[[@CR43]\]RT-PCRNANANADemyelinating with sural sparingAIDPThoracic and lumbar spine: no evidence of myelopathy or radiculopathyIVIG 400 mg/kg (5 days)Hydroxychloroquine and azithromycinOn day 4 respiratory improvement, on day 7 rehabilitationReyes-Bueno et al. \[[@CR44]\]Serology (negative RT-PCR)NANegative anti-ganglioside antibodiesIncreased total protein (70 mg/dl), cell count: 5 cells/µl, albuminocytological dissociationDemyelinating with alteration of the Blink-Reflex. Further EMG: polyradiculoneuropathy with proximal and brainstem involvementAIDPNAIVIG 400 mg/kg (5 days) + GabapentinNAAfter the 18th day progressive improvement of  facial and limb paresis, diplopia and pain. Consequent neurological rehabilitationRiva et al. \[[@CR45]\]Chest CT + serology (negative RT-PCR)No pathological findingsNegative anti-ganglioside antibodiesNormal total protein and cells; negative PCR for SARS-CoV2, EBV, CMV, VZV, HSV 1--2, HIVDemyelinating with sural sparingAIDPBrain: NASpinal: no pathological findingsIVIG 400 mg/kg (5 days)NoneSlowly improvement after the 10th daySancho-Saldaña et al. \[[@CR46]\]RT-PCR + chest X-RayNANegative anti-ganglioside antibodiesIncreased total protein (0.86 g/L), cell count: 3 leucocytesDemyelinatingAIDPWhole spine: brainstem and cervical meningeal enhancementIVIG 400 mg/kg (5 days)Hydroxychloroquine, azithromycinRecovering by day 7 after the onset of weakness.Scheidl et al. \[[@CR47]\]RT-PCRNo pathological findingsNegative *Campylobacter Jejuni* and Borrelia serology, negative ANA, anti-DNA, c-ANCA,p-ANCAIncreased total protein (140 g/L), albuminocytological dissociationDemyelinatingAIDPBrain: NACervical spine: no pathological findingsIVIG 400 mg/kg (5 days)NoneComplete recoverySedaghat et al. \[[@CR48]\]RT-PCR + chest CTIncreased WBC 14.6 × 10^3^ (neutrophils 82.7%, lymphocytes 10.4%) and CRPNANAMotor sensory AxonalAMSANBrain: no pathological findingsSpinal: two cervical intervertebral disc herniationsIVIG 400 mg/kg (5 days)Hydroxychloroquine, lopinavir/ritonavir, azithromycinNot reportedSidig et al. \[[@CR49]\]RT-PCR + chest CTNANANoneDemyelinatingAIDPBrain: no pathological findingsNANADeath after 7 days; because of progressive respiratory failureSu et al. \[[@CR50]\]RT-PCR + chest X-rayWBC 12,000 cells/µlNegative anti- ganglioside GM1, GD1b and GQ1b antibodies, acetylcholine receptor binding, voltage-gated calcium channel, antinuclear and ANCAIncreased total protein (313 mg/dL), WBC: 1 cellDemyelinatingAIDPNAIVIG 2gm/kg (for 4 days)NoneOn day 28 persistence of severe weaknessTiet et al. \[[@CR51]\]RT-PCRElevated lactate on venous blood gas (3.3 mmo/L), mildly elevated CRP (20 mg/L). Normal WBC, sodium, potassium and renal function.NAIncreased total protein (\> 1.25 g/L), cell count 1x10^6^/LDemyelinatingAIDPNAIVIG 400 mg/kg/day (5 days)NoneResolution of facial diplegia, improved upper and lower limbs weakness; able to mobilize unassisted 11 weaks after neurorehabilitationToscano et al. \[[@CR52]\]RT-PCR + Chest CT + serologyLymphocytopenia, increased CRP, LDH, ketonuriaNegative anti-ganglioside antibodiesDay 2: normal total protein, no cells, negative SARS-CoV-2 PCRDay 10: increased total protein (101) mg/dl, cell count: 4/mm^3^, negative SARS-CoV-2 PCRAxonal with sural sparingAMSANBrain: no pathological findingsSpinal: Enhancement of caudal nerve rootsIVIG 400 mg/kg (2 cycles) + temporary mechanical non-invasive ventilationParacetamolAt week 4 persistence of severe UL weakness, dysphagia, and LL paraplegiaToscano et al. \[[@CR52]\]RT-PCR (negative chest CT)Lymphocytopenia; increased ferritin, CRP, LDHNAIncreased total protein (123 mg/dl), no cells, negative SARS-CoV-2 PCRMotor sensory axonal with sural sparingAMSANBrain: enhancement of facial nerve bilaterallySpinal: no pathological findingsIVIG 400 mg/kgAmoxycillinAt week 4 improvement of  ataxia and mild improvement of  facial weaknessToscano et al. \[[@CR52]\]RT-PCR + chest CTLymphocytopenia; increased CRP, LDH, ketonuriaNegative anti-ganglioside antibodiesIncreased total protein (193 mg/dl), no cells, negative SARS-CoV-2 PCRMotor axonalAMANBrain: no pathological findingsSpinal: enhancement of caudal nerve rootsIVIG 400 mg/kg (2 cycles) + mechanical invasive ventilationAzythromicinICU admission due to respiratory failure and tetraplegia. At week 4 still criticalToscano et al. \[[@CR52]\]RT-PCR + serology (negative chest CT)Lymphocytopenia; increased CRP, ketonuriaNANormal protein, no cells, negative SARS-CoV-2 PCRDemyelinatingAIDPBrain: no pathological findingsSpinal: no pathological findingsIVIG 400 mg/kgNoneAt week 4 mild improvement in UL but unable to standToscano et al. \[[@CR52]\]Chest CT + serology (negative RT-PCR in nasopharyngeal swab and BAL)Lymphocytopenia; increased CRP, LDHNegative anti-ganglioside antibodies; negative screening for *Campylobacter jejuni*, EBV, CMV, HSV, VZV, influenza, HIVNormal total protein (40 mg/dL), white cell count 3/mm^3^; negative SARS-CoV-2 PCRDemyelinatingAIDPBrain: NASpinal: no pathological findingsIVIG 400 mg/kg + plasma exchange + mechanical invasive ventilation + enteral nutritionNoneAt week 4 flaccid tetraplegia, dysphagia, ventilation dependentVelayos Galán et al. \[[@CR53]\]RT-PCR + chest X-rayNANANADemyelinatingAIDPNAIVIG 400 mg/kg (5 days)Hydroxychloroquine, lopinavir/ritonavir, amoxicillin, corticosteroids + low-flow oxygen therapyNAVirani et al. \[[@CR54]\]rt-pcr + chest mrtWBC 8.6 × 10^3^; Hb 15.4 g/dl; PC 211 × 10^3^; procalcitonin: 0.15 ng/mlNANANABrain: NASpinal: no pathological findingsIVIG 400 mg/kg (5 days) + mechanical invasive ventilation (4 days)Hydroxychloroquine 400 mg bid for first 2 doses, then 200 mg bid for 8 dosesAt day 4 of IVIG: liberation from mechanical ventilation, resolution of UL symptoms, persistence of LL weakness. Sent to a rehabilitation facilityWebb et al. \[[@CR55]\]RT-PCR + chest X-ray + chest CTLymphopenia (0.9 × 10^9^/L), thrombocytosis (490 × 10^9^/L) raised CRP (25 mg/L)Negative ANA, ANCA, anti-ganglioside antibodies, syphilis serology HIV, hepatitis B and hepatitis CIncreased total protein (0.51 g/L), normal glucose and cell count, negative SARS-CoV-2 PCR, negative viral PCRDemyelinatingAIDPNAIVIG 400 mg/kg/day (5 days) + Mechanical invasiveventilationCo-amoxiclavAfter 1 week in ICU: no oxygen requirement and ventilationZhao et al. \[[@CR56]\]RT-PCR + chest CTWBC 0.52 × 10^9^; PC 113 × 10^9^/LNAIncreased total protein (124 mg/dL), cell count 5 × 10^6^/LDemyelinatingAIDPNAIVIG (dosing not reported)Arbidol, lopinavir/ ritonavirAt day 30 resolution of neurological and respiratory symptomsAIDP, acute inflammatory demyelinating polyneuropathy; AMAN, acute motor axonal neuropathy; AMSAN, acute motor sensory axonal neuropathy; ANA, antinuclear antibodies; ANCA, anti-neutrophil cytoplasmic antibodies; BAL, bronchoalveolar lavage; CK, creatine kinase; CMV, cytomegalovirus; COPD, chronic obstructive pulmonary disease, COVID-19, coronavirus disease 2019; CRP, C-reactive protein; CSF, cerebrospinal fluid; CT, computed tomography; DM, diabetes mellitus; EBV, Epstein--Barr virus; ESR, erythrocyte sedimentation rate; F, female; GBS, Guillain--Barré syndrome; GGT, gamma-glutamyl transferase; GOT, glutamic oxaloacetic transaminase; GPT, glutamate pyruvate transaminase; Hb, haemoglobin; HIV, human immunodeficiency virus; HSV, herpex simplex virus; ICU, intensive-care unit; IL, interleukin; IVIG, intravenous immunoglobulins; IL, interleukin; LDH, lactate dehydrogenase; LL, lower limbs; M, male; MRI, magnetic resonance imaging; NA, not available; PC, platelet count; PCR, Polymerase Chain Reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus-2; TNF, tumor necrosis factor; UL, upper limbs; VDRL, Veneral Disease Research Laboratory; VZV, varicella-zoster virus; WBC, white blood cells; X-ray: radiography^a^Time to Nadir refers to days elapsed between the onset of neurological symptoms and the development of the worst clinical picture when no progression was reported nadir was considered concomitant with GBS symptoms onset^b^According to Brighton diagnostic criteria \[[@CR66]\]

Interestingly, patients with no improvement or poor outcome (*n* = 19) showed a slightly higher (but not significant) frequency of clinical history and/or a radiological picture of COVID-19 pneumonia (14/19, 73.7%) compared to those with a favorable prognosis (29/48, 60.4%, *p* = 0.541). Moreover, the former group of patients was significantly older (mean 62.7 ± 17.8 years, *p* = 0.011), but with comparable distribution of sex (*p* = 0.622) and electrophysiological subtypes (*p* = 0.144) and similar latency between COVID-19 and GBS (*p* = 0.588) and nadir (*p* = 0.825), compared to the latter (mean age 51.8 ± 16.6 years). The same findings were confirmed even after excluding cases with no improvement from the analysis (to prevent a possible bias related to the short follow-up time).

Discussion {#Sec10}
==========

COVID-19 pandemic prompts all efforts for the early recognition and treatment of its manifestations. In analogy to other viruses, belonging or not to the coronavirus family \[[@CR63], [@CR67]\], neurologic complications in COVID-19 are emerging as one of the most significant clinical chapters of this pandemic. In this regard, peripheral and central nervous system damage in COVID-19 has been postulated to be the consequence of two different mechanisms: 1) hematogenous (infection of endothelial cells or leucocytes) or trans-neuronal (via olfactory tract or other cranial nerves) dissemination to central nervous system in relation with viral neurotropism, and 2) abnormal immune-mediated response causing secondary neurological involvement \[[@CR62], [@CR68], [@CR69]\]. The first mechanism is supposed to be responsible for the most common neurological symptoms developed by patients with COVID-19 (e.g., hypogeusia, hyposmia, headache, vertigo, and dizziness). In contrast, the second can lead to severe complications during or after the course of the illness, either dysimmune (e.g., myelitis, encephalitis, GBS) or induced by cytokine overproduction (hypercoagulable state and cerebrovascular events) \[[@CR68], [@CR69]\].

In the present systematic review, we reviewed clinical features, results of diagnostic investigations, and outcome in 73 cases of COVID-19-associated GBS spectrum \[[@CR5]--[@CR56]\].

In the present study, mean age at onset in patients with GBS largely overlapped that of classic COVID-19 subjects \[[@CR70], [@CR71]\]. However, pediatric cases with GBS have been increasingly reported in the literature \[[@CR21], [@CR27], [@CR35], [@CR41]\], suggesting that, with the spreading of the pandemic, a broader age range might be affected. Moreover, we found a higher prevalence of GBS in males compared to females, as previously reported for Zika virus--GBS \[[@CR72]\]. This finding may also reflect the gender epidemiology of SARS-CoV-2. In this regard, males typically show a worse COVID-19 outcome compared to the females \[[@CR70], [@CR71]\], possibly due to a generally shorter life expectancy or to higher circulating Angiotensin-Converting-Enzyme 2 (ACE2) levels, the cellular receptor for SARS-CoV-2, in the former compared to the latter \[[@CR71]\]. Moreover, given that GBS is a rare disease \[[@CR57]\] the epidemiological distribution of the reported cases seems to reflect current worldwide outbreaks, with Europe being the "hottest" spot in March--May 2020 and USA together with Asia in the following period \[[@CR73], [@CR74]\]. On another issue, despite a few GBS cases seemed to have a para-infectious profile \[[@CR10], [@CR37], [@CR38], [@CR40], [@CR55], [@CR56]\] as described for Zika virus \[[@CR75]\], all other reported patients developed neurological symptoms with a typical latency after COVID-19 (median time 14 days). This feature, together with the frequently reported negative nasopharyngeal swab at GBS onset \[[@CR22], [@CR24], [@CR36], [@CR44], [@CR45], [@CR52]\] and clinical improvement after IVIG therapy, seems to support the notion of a prominent post-infectious immune-mediated mechanism. However, in this context, the massive release of cytokines in COVID-19 may also contribute to the amplification of the dysimmune process underlying GBS \[[@CR76], [@CR77]\]. In this regard, the increase of blood inflammatory markers (e.g., CRP, IL-6, TNF-α, IL-1, etc.) in GBS tested cases may reinforce the hypothesis of a systemic inflammatory storm in COVID-19 \[[@CR76], [@CR77]\]. However, given the limited data, we could not perform an accurate analysis of the distribution and, eventually, prognostic value of inflammatory markers in COVID-19-associated GBS. Moreover, we cannot exclude that in cases with GBS developing before or together with COVID-19 symptoms, the disease might have progressed sub-clinically in the early phase to manifest afterwards with its typical systemic clinical picture. Indeed, two cases \[[@CR10], [@CR12]**\]**, who tested positive for SARS-CoV-2, never developed COVID-19 respiratory or systemic symptoms and one of them showed an asymptomatic pneumonia at chest-CT \[[@CR12]\]. However, only more extensive epidemiological and translational studies, with the aim to compare the characteristics of GBS associated or not with COVID-19, could clarify these issues.

In our population, most common clinical manifestations and distribution of clinical variants resemble those of classic GBS confirming the predominance of the sensorimotor syndrome compared to MFS and other rare variants \[[@CR57]--[@CR59], [@CR66]\]. Similarly, the results of CSF analysis reflected typical neurochemical findings in non-COVID-19 GBS. In the latter, elevated CSF proteins and pleocytosis were described in about 50--80% \[[@CR57], [@CR78]\] and 11--15% cases, respectively \[[@CR58], [@CR79], [@CR80]\], largely overlapping with the percentages in our cohort. In this regard, the mostly normal cell count, together with the absence of SARS-CoV-2 RNA in all tested CSF samples \[[@CR6]--[@CR9], [@CR12]--[@CR14], [@CR16], [@CR21]--[@CR24], [@CR31], [@CR33], [@CR36], [@CR42], [@CR44], [@CR52], [@CR55]\], makes the possibility of a direct invasion from SARS-CoV-2 into the nerve roots with intrathecal viral replication less probable. However, a possible bias might rely on the lack of systematic data concerning the latency between symptom onset and CSF sampling in COVID-19 GBS cases. On another issue, in a further case of MFS associated withCOVID-19, who came to our attention, we observed the absence of intrathecal synthesis of SARS-CoV-2 antibodies together with a massive increase of CSF phosphorylated neurofilament heavy chain (pNfH) and serum neurofilament light chain (NfL) proteins, supporting the role of neurochemical markers as easily implementable tools for the detection of nervous system affection in COVID-19-related diseases \[[@CR81], [@CR82]\].

At variance with CSF findings, we found a discrepancy concerning MRI findings between classic GBS and COVID-19-related GBS. Specifically, while most cases of the former group showed typically spinal root enhancement at MRI \[[@CR83]\], in the latter group, in analogy with Zika-associated GBS, the same finding was less frequently reported \[[@CR84]\]. However, caution should be warranted in the interpretation of these results, given that MRI findings might have been underestimated, due to lack of a sufficient number of exams in the context of pandemic-imposed restrictions in the routine clinical setting.

Regarding the distribution of GBS electrophysiological variants, our analysis showed that COVID-19-associated GBS manifests prevalently with AIDP and, to a lesser extent, with AMSAN and AMAN, in line with classic GBS in Western countries \[[@CR66], [@CR85]\]. Conversely, the observation of positive anti-GD1b antibodies  in one COVID-19-related MFS patient and negative anti-ganglioside antibodies in other five cases appear in discordance with the high prevalence (≈ 90%) of anti-GQ1b antibodies among non-COVID-19 MFS cases \[[@CR86]\], and may suggest different immune-mediated mechanisms. However, these results could not be generalized until a wider population would be tested.

In analogy to classic GBS, approximately one-fifth of COVID-19-associated GBS subjects required mechanical ventilation during hospitalisation \[[@CR87]\]. In this regard, cases with no improvement or unfavorable outcome showed, in comparison to those with a good prognosis, an older age, confirming similar findings both in classic GBS \[[@CR58], [@CR88]\] and in COVID-19 \[[@CR89]\], and a slightly higher frequency (without reaching a statistical significance) of past or concurrent COVID-19 pneumonia. However, given the short follow-up time in most cases, we could not reach a definite conclusion on the impact of past or concurrent COVID-19 restrictive syndrome due to pneumonia on the prognosis of GBS patients. Future prospective studies are needed to clarify this issue. Moreover, given that also preceding diarrhea (mostly caused by *Campylobacter Jejuni* infection) is a strong negative prognostic factor in classic GBS \[[@CR57], [@CR88]\], further prospective studies are needed to compare the severity of GBS related to COVID-19 to that associated with *C. jejuni*. Finally, in the context of respiratory failure and ventilation associated with COVID-19, the differential diagnosis should always take into consideration critical illness neuropathy and myopathy, which tend to develop later during the critical course \[[@CR90]\]. Despite these findings, approximately one-third of COVID-19-related GBS patients showed no clinical and/or radiological evidence of pneumonia, providing evidence that GBS may also develop in the context of a paucisymptomatic or even asymptomatic COVID-19. However, given that among the GBS population only two asymptomatic COVID-19 patients were reported to date, we may speculate that, in most cases, a certain degree of lung injury (even minimal) or at least hematic dissemination (e.g., fever underlying significant viral load) is necessary to trigger the immuno-mediated process through lymphocytic recognition of self-antigens or molecular mimicry.

Major strengths of our review are the inclusion of a high number of patients, together with an in-depth analysis of the clinical and diagnostic features of COVID-19-associated GBS. We are aware that selection bias might have occurred, given that most reported cases to date have been described mostly in Europe (47 out of 73) and during COVID-19 highest spreading. Therefore, future extensive epidemiological studies are necessary to ascertain the nature of the association between COVID-19 and GBS (causal or coincidental). Moreover, we cannot exclude the possibility that at least some of the cases represent instances of CIDP, given the frequent absence of a follow-up longer than 2 months. On another issue, the low but possible evidence of an epidemiological link between vaccines and GBS development \[[@CR57], [@CR58]\] should aware the clinicians of the possible occurrence of GBS after COVID-19 vaccination in the long-term future.

In conclusion, based on the systematic review of 73 cases, we showed that the clinical picture of COVID-19-associated GBS seems to resemble that of classic GBS or Zika-associated GBS. Moreover, the chronological evolution, the response to IVIG, and the absence of SARS-CoV-2 RNA in CSF may suggest a prominent post-infectious immune-mediated mechanism rather than a para-infectious one. Although most cases were symptomatic for COVID-19, the preliminary report of a few patients without respiratory or systemic symptoms raises a significant healthcare issue, namely the importance of SARS-CoV-2 testing in all patients with suspected GBS during the pandemic, with the aim to provide an eventual rapid case isolation. Nevertheless, only further analyses on more comprehensive cohorts could help in clarifying better all these issues.
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